Abstract:To reduce time and cost, virtual ligand screening (VLS) often precedes experimental ligand screening in modern drug discovery. Traditionally, high-resolution structure-based docking approaches rely on experimental structures, while ligand-based approaches need known binders to the target protein and only explore their nearby chemical space. In contrast, our structure-based FINDSITEcomb2.0 approach takes advantage of predicted, low-resolution structures and information from ligands that bind distantly related proteins whose binding sites are similar to the target protein. Using a boosted tree regression machine learning framework, we significantly improved FINDSITEcomb2.0 by integrating ligand fragment scores as encoded by molecular fingerprints with the global ligand similarity scores of FINDSITEcomb2.0. The new approach, FRAGSITE, exploits our observation that ligand fragments, e.g., rings, tend to interact with stereochemically conserved protein subpockets that also occur in evolutionarily unrelated proteins. FRAGSITE was benchmarked on the 102 protein DUD-E set, where any template protein whose sequence identify >30% to the target was excluded. Within the top 100 ranked molecules, FRAGSITE improves VLS precision and recall by 14.3 and 18.5%, respectively, relative to FINDSITEcomb2.0. Moreover, the mean top 1% enrichment factor increases from 25.2 to 30.2. On average, both outperform state-of-the-art deep learning-based methods such as AtomNet. On the more challenging unbiased set LIT-PCBA, FRAGSITE also shows better performance than ligand similarity-based and docking approaches such as two-dimensional ECFP4 and Surflex-Dock v.3066. On a subset of 23 targets from DEKOIS 2.0, FRAGSITE shows much better performance than the boosted tree regression-based, vScreenML scoring function. Experimental testing of FRAGSITE's predictions shows that it has more hits and covers a more diverse region of chemical space than FINDSITEcomb2.0. For the two proteins that were experimentally tested, DHFR, a well-studied protein that catalyzes the conversion of dihydrofolate to tetrahydrofolate, and the kinase ACVR1, FRAGSITE identified new small-molecule nanomolar binders. Interestingly, one new binder of DHFR is a kinase inhibitor predicted to bind in a new subpocket. For ACVR1, FRAGSITE identified new molecules that have diverse scaffolds and estimated nanomolar to micromolar affinities. Thus, FRAGSITE shows significant improvement over prior state-of-the-art ligand virtual screening approaches. A web server is freely available for academic users at <a class="extLink" href="http://http:/sites.gatech.edu/cssb/FRAGSITE">http:/sites.gatech.edu/cssb/FRAGSITE</a>.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c01160?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c01160</a>.Additional information for experimental methods and (Tables S1 and S2) top 40 most frequent fragments in DrugBank drugs and performance of methods for individual DUD-E targets using the modeled target structure (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c01160/suppl_file/ci0c01160_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

KinaFrag Explores the Kinase-Ligand Fragment Interaction Space for Selective Kinase Inhibitor Discovery

Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations

Fragment-based Drug Discovery and Molecular Docking in Drug Design.

Fragment-based drug design facilitates selective kinase inhibitor discovery

FRAGSITE: A Fragment-Based Approach for Virtual Ligand Screening

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with -Substituent Electrophiles Targeting Cysteine

Discovery and Computational Studies of Potent Covalent Kinase Inhibitors with alpha-Substituent Electrophiles Targeting Cysteine

A minimalist approach to fragment-based ligand design using common rings and linkers: application to kinase inhibitors

PADFrag: A Database Built for the Exploration of Bioactive Fragment Space for Drug Discovery.

Kinase Inhibitor Data Modeling and De Novo Inhibitor Design with Fragment Approaches.

A comparative study of fragment screening methods on the p38α kinase: new methods, new insights

In silico construction of a focused fragment library facilitating exploration of chemical space**

Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery

Crystallographic fragment screening of CDK2-cyclin A: FragLites map sites of protein-protein interaction

Fragmenstein: predicting protein-ligand structures of compounds derived from known crystallographic fragment hits using a strict conserved-binding–based methodology

KLSD: a kinase database focused on ligand similarity and diversity

ACFIS: a web server for fragment-based drug discovery.

Fragment-Based Computational Method for Designing GPCR Ligands

The Discovery of Novel Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibitors: Pharmacophore Modeling, Virtual Screening and Docking Studies

Reaction-Based Enumeration, Active Learning, and Free Energy Calculations To Rapidly Explore Synthetically Tractable Chemical Space and Optimize Potency of Cyclin-Dependent Kinase 2 Inhibitors

Deep Geometry Handling and Fragment-wise Molecular 3D Graph Generation